A Share Price | Agilent Technologies, Inc. Stock Analysis & Recommendation

Q: What does Agilent Technologies, Inc. do?

Overview:Agilent Technologies, Inc. provides application-focused solutions, including instruments, software, services, and consumables for laboratory workflows, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.Financial Snapshot:Most recent Net Sales: 1,668 Million (Quarterly Results - Apr 2025) Most recent Net Profit: 215 Million (Quarterly Results - Apr 2025) Market cap: USD 32,977.07 Million (Large Cap)Key Metrics:P/E: 25.00 Dividend Yield: 64.19% Debt Equity: 0.33 Return on Equity: 21.31% Price to Book: 5.37 Contact Details:Address: 5301 Stevens Creek Blvd, SANTA CLARA CA: 95051-7201 Tel: 1 408 3458886 Fax: 1 408 3458474 Website: https://www.agilent.com/

Q: Who are in the management team of Agilent Technologies, Inc.?

As of March 2022, the management team of Agilent Technologies, Inc. includes the following individuals:- Mr. Boon Hwee Koh, who serves as the Non-Executive Independent Chairman of the Board.- Mr. Michael McMullen, who is the President, Chief Executive Officer, and a Director.- Ms. Mala Anand, who is an Independent Director.- Mr. Hans Bishop, who is also an Independent Director.- Mr. Paul Clark, who serves as an Independent Director.- Ms. Heidi Kunz, who is an Independent Director.This team is responsible for guiding the company's strategic direction and governance.

Q: Is Agilent Technologies, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Agilent Technologies, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting a positive outlook. Additionally, the daily moving averages are bullish, while the Bollinger Bands indicate a mildly bullish stance on the weekly and a bullish stance on the monthly. The KST shows a bullish signal weekly but bearish monthly, and the Dow Theory indicates a mildly bullish trend on a monthly basis.In terms of performance, Agilent's returns over the past week and month are significantly higher than the S&P 500, with a 14.43% return over the past week compared to 1.09% for the index, and a 9.99% return over the past month versus 4.15%. However, the longer-term returns, particularly over the past year and three years, lag behind the S&P 500.Overall, the current technical stance is mildly bullish, driven primarily by the positive signals from MACD and moving averages.

Q: Is Agilent Technologies, Inc. overvalued or undervalued?

As of 17 October 2025, Agilent Technologies, Inc. has moved from a very expensive valuation to fair. The company is currently fairly valued based on its financial metrics, with a P/E ratio of 25, an EV to EBITDA of 18.73, and a Price to Book Value of 5.36. In comparison, peers such as Edwards Lifesciences Corp. have a higher P/E of 31.17, while DexCom, Inc. is even more expensive with a P/E of 53.65, indicating that Agilent is relatively more attractively priced within its industry.Despite its fair valuation, Agilent's recent stock performance has lagged behind the S&P 500, returning only 3.27% over the past year compared to the S&P 500's 14.08%. However, it has shown stronger returns over shorter periods, with a 1-month return of 11.99% versus the S&P 500's 0.96%. Overall, Agilent's valuation appears reasonable given its competitive positioning and performance metrics.

Mojo Score Change: Agilent Technologies, Inc. has changed its score on 20 Mar 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.38 M

Shareholding (Jan 2026)

FII

29.32%

Held by 470 FIIs

DII

30.3%

Held by 70 DIIs

Promoter

0.04%

How big is Agilent Technologies, Inc.?

22-Jun-2025

As of Jun 18, Agilent Technologies, Inc. has a market capitalization of $32.98 billion, with net sales of $6.63 billion and net profit of $1.17 billion over the latest four quarters.

View full answer

What does Agilent Technologies, Inc. do?

22-Jun-2025

Agilent Technologies, Inc. offers application-focused solutions for laboratory workflows in the Pharmaceuticals & Biotechnology industry, with recent net sales of $1.668 billion and a market cap of approximately $32.98 billion. Key financial metrics include a P/E ratio of 25.00 and a dividend yield of 64.19%.

View full answer

Who are in the management team of Agilent Technologies, Inc.?

22-Jun-2025

As of March 2022, Agilent Technologies, Inc.'s management team includes Non-Executive Independent Chairman Boon Hwee Koh, President and CEO Michael McMullen, and Independent Directors Mala Anand, Hans Bishop, Paul Clark, and Heidi Kunz. They oversee the company's strategic direction and governance.

View full answer

Is Agilent Technologies, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Agilent Technologies, Inc. shows a mildly bullish trend supported by positive MACD signals and strong recent performance compared to the S&P 500, despite lagging in longer-term returns.

View full answer

Is Agilent Technologies, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Agilent Technologies is fairly valued with a P/E ratio of 25, lagging behind the S&P 500 with a 3.27% return over the past year, but showing stronger short-term performance with an 11.99% return in the last month.

View full answer

Compare Agilent Technologies, Inc. with Similar Stocks

IDEXX Laboratories, Inc.DexCom, Inc.Edwards Lifesciences Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 20.72%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.90 times

Flat results in Jul 25

With ROCE of 19.48%, it has a fair valuation with a 4.29 Enterprise value to Capital Employed

High Institutional Holdings at 93.78%

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 31,603 Million (Mid Cap)

P/E

22.00

Industry P/E

Dividend Yield

0.90%

Debt Equity

0.24

Return on Equity

20.86%

Price to Book

4.69

Revenue and Profits:

Net Sales:

1,798 Million

(Quarterly Results - Jan 2026)

Net Profit:

305 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.7%

6 Months

-12.79%

1 Year

-9.59%

2 Years

-23.81%

3 Years

-16.43%

4 Years

-20.0%

5 Years

-9.21%

Agilent Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.41%

EBIT Growth (5y)

10.45%

EBIT to Interest (avg)

16.82

Debt to EBITDA (avg)

0.90

Net Debt to Equity (avg)

0.33

Sales to Capital Employed (avg)

0.73

Tax Ratio

14.95%

Dividend Payout Ratio

21.70%

Pledged Shares

Institutional Holding

94.40%

ROCE (avg)

20.72%

ROE (avg)

22.25%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.69

EV to EBIT

21.15

EV to EBITDA

17.88

EV to Capital Employed

3.98

EV to Sales

4.78

PEG Ratio

5.52

Dividend Yield

0.90%

ROCE (Latest)

18.80%

ROE (Latest)

20.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jan 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 155 Schemes (40.27%)

Foreign Institutions

Held by 470 Foreign Institutions (29.32%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jan'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jan 2026 is -3.39% vs 7.08% in Oct 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jan 2026 is -29.72% vs 29.17% in Oct 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jan'26",
        "Oct'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,798.00",
          "val2": "1,861.00",
          "chgp": "-3.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "442.00",
          "val2": "514.00",
          "chgp": "-14.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "24.00",
          "val2": "27.00",
          "chgp": "-11.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-18.00",
          "val2": "-11.00",
          "chgp": "-63.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "305.00",
          "val2": "434.00",
          "chgp": "-29.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "208.60%",
          "val2": "238.00%",
          "chgp": "-2.94%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2025 is 6.73% vs -4.73% in Oct 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2025 is 1.09% vs 3.95% in Oct 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Oct'25",
        "Oct'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,948.00",
          "val2": "6,510.00",
          "chgp": "6.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,852.00",
          "val2": "1,850.00",
          "chgp": "0.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "111.00",
          "val2": "96.00",
          "chgp": "15.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-129.00",
          "val2": "-83.00",
          "chgp": "-55.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,303.00",
          "val2": "1,289.00",
          "chgp": "1.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "225.10%",
          "val2": "244.70%",
          "chgp": "-1.96%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jan'26 - QoQ

Jan'26

Oct'25

Change(%)

Net Sales

1,798.00

1,861.00

-3.39%

Operating Profit (PBDIT) excl Other Income

442.00

514.00

-14.01%

Interest

24.00

27.00

-11.11%

Exceptional Items

-18.00

-11.00

-63.64%

Consolidate Net Profit

305.00

434.00

-29.72%

Operating Profit Margin (Excl OI)

208.60%

238.00%

-2.94%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jan 2026 is -3.39% vs 7.08% in Oct 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jan 2026 is -29.72% vs 29.17% in Oct 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Oct'25

Oct'25

Oct'24

Change(%)

Net Sales

6,948.00

6,510.00

6.73%

Operating Profit (PBDIT) excl Other Income

1,852.00

1,850.00

0.11%

Interest

111.00

96.00

15.62%

Exceptional Items

-129.00

-83.00

-55.42%

Consolidate Net Profit

1,303.00

1,289.00

1.09%

Operating Profit Margin (Excl OI)

225.10%

244.70%

-1.96%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Oct 2025 is 6.73% vs -4.73% in Oct 2024

Consolidated Net Profit

YoY Growth in year ended Oct 2025 is 1.09% vs 3.95% in Oct 2024

All Annual Results

Company CV

About Agilent Technologies, Inc.

Agilent Technologies, Inc.

Pharmaceuticals & Biotechnology

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.

Company Coordinates

Company Details

5301 Stevens Creek Blvd , SANTA CLARA CA : 95051-7201

Tel: 1 408 3458886

https://www.agilent.com/

Registrar Details